Cardiovascular Disease

Based on guidance from the American Society of Preventive Cardiology, this topline summarizes risk factors and interventions to reduce the risk of major adverse CV events.

The risk for developing CVD and T2D was highest among individuals who frequently experienced the behavior in the workplace, according to new study.

Your daily dose of the clinical news you may have missed.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Your daily dose of the clinical news you may have missed.

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Your daily dose of the clinical news you may have missed.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.

Your daily dose of the clinical news you may have missed.

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

Find details on a novel web tool found to help patients determine their eligibility for OTC statin use, FDA clearance of the first AI-based algorithm to detect HF during routine exams, and more.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Findings suggest that optimizing care for children with hypertension may reduce the risk of adult CVD, report researchers.

Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.

Poor cardiovascular health at midlife was associated with a decline in the mental processing speed of Black women, but not White women, according to a new study.

Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.

The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

Your daily dose of the clinical news you may have missed.

ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.